RUO · Research Use Only⚠ Russian-only dataFor LongTelomere claim+2 more

Epitalon

A four-amino-acid peptide developed in the Soviet Union by Vladimir Khavinson. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 9 minEvidence ●○○○○Citations 60

+ Add to Stack⚖ Compare

⚖ Compare side-by-side ⎙ Print companion card

Free — puts Epitalon on your decision board.

The Epitalon Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status

Research-only

Class

Russian-only data

Evidence

1/ 5●○○○○

Independently replicated trials

$19 ↓

Khavinson-group share of our citations

23 of 60 citations are from the Khavinson group

Western Phase 2/3 trials

$19 ↓

⚠ Russian-only data

Read this if

you've fallen into the longevity podcast rabbit hole
Bryan Johnson's Blueprint stack made you curious
you're trying to sort the real signal from longevity-forum noise on telomere extension

Skip this if

**the telomere claim is unfalsifiable to a consumer** — there is no at-home test that meaningfully tracks telomere length over a 10–20-day Epitalon cycle; you're paying for an effect you literally cannot verify
you have active or recent cancer or strong cancer family history — **telomerase reactivation is one of the hallmarks tumors exploit to escape replicative limits** (Hanahan & Weinberg 2011 PMID 21376230); a peptide pitched on "extending the replicative limit" is mechanism-flagged in that direction
you want strong human evidence — there isn't much yet
you're looking for fat loss, recovery, or muscle gain
you're allergic to Russian peptide research that hasn't been replicated in the West

The 4 ways you can buy Epitalon

No FDA-approved epitalon exists.

Compounded 503A

✓

Off-label

$80–$200/mo where sold

Mid–high. Few compounders carry; the Khavinson-only evidence base means legitimacy is weak.

RUO (research-only)

✓

Sold 'for research only'

$25–$80/mo

The dominant supply; small tetrapeptide is cheap to synthesize.

Gray market

✓

Unregulated overseas import

$35–$75/mo

Crypto/Wise pay; the 50mg×10 boxes ($176, $0.35/mg) are the bulk-buy tier — one box covers years a…

Click any lane for the full Sourcing breakdown. Prices and lane availability vary by molecule — this is the per-peptide snapshot, not a generic table.

First 90 days · Epitalon

What we'd actually do

Weeks 1–2

Nothing perceptible. Longevity peptides are not 'feel something' molecules. If a vendor says you'll notice an effect this fast, they're selling you on placebo.

Weeks 4–8

Possibly subtle shifts in biomarkers (inflammation, sleep, recovery). Subjective changes in this window are usually placebo and confounded with whatever else you changed.

Week 12 — decide

Bloodwork or biomarker check. If the protocol can't be defended on a labeled change at 12 weeks, it can't be defended on hope.

Quit if

Any unusual symptoms — especially the cancer-mechanism flag for angiogenic peptides.
12 weeks of continuous use with no objective biomarker support to keep going.
Tolerance signal (the protocol needs escalating doses to feel the same).

Identity

What it is.

Epitalon is a four-amino-acid (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, starting in the 1980s. It's a synthetic analog of a longer pineal-gland peptide called epithalamin.

The pitch, in Khavinson's framing: short bioregulator peptides that nudge specific tissues back toward youthful gene-expression patterns. Epitalon is the pineal-targeted member of the family. The marketed effects center on telomere maintenance, sleep architecture, and circadian regulation.

It is sold strictly as a research chemical (RUO) in the US and Europe. There is no version. In Russia and a small number of post-Soviet states, related Khavinson peptides have been used in clinic settings, but the regulatory framework there is not equivalent to FDA approval.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Epitalon actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓

Mechanism

Mechanism.

Mechanism · in the Epitalon report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓

Evidence

Evidence. What we actually know in humans.

Evidence · in the Epitalon report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓

Human-Evidence Factbox

Independently replicated trials

$19 ↓

Khavinson-group share of our citations

23 of 60 citations are from the Khavinson group

Western Phase 2/3 trials

$19 ↓

Half-life

$19 ↓

WADA status

$19 ↓

Long-term safety data

$19 ↓

Dose

Dose. The actual protocol.

Dose · in the Epitalon report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.

Get the report · $19 ↓

Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Epitalon report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.

Get the report · $19 ↓

Safety

Safety. Side effects.

Safety · in the Epitalon report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓

Editorial Position

Editorial position.

Editorial Position · in the Epitalon report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓

Citations

Citations.

+Show all 60 citations

The Epitalon Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.

Compare tiers →